Drugs / Anti-CD19-CAR CMV-specific T-lymphocytes
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06735690 | Dec 2025 → Mar 2029 expected | acute lymphoblastic leukemia | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05801913 | Sep 2023 → Mar 2028 expected | high grade B-cell lymphoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05432635 | Aug 2023 → Mar 2028 expected | diffuse large B-cell lymphoma, mantle cell lymphoma | City of Hope Medical Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD19-CAR CMV-specific T-lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05801913 ↗ |
| Action | Deplete | “CAR T-cells are a type of treatment in which a patient's T-cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells.” NCT05432635 ↗ |
| Modality | Cell therapy | “CAR T-cells are a type of treatment in which a patient's T-cells (a type of immune system cell) are changed in the laboratory” NCT05432635 ↗ |
| Route | Intravenous | “Given IV” NCT05432635 ↗ |
| Target | CD19 | “Anti-CD19-CAR CMV-specific T-lymphocytes” NCT05432635 ↗ |